The ELF test, which forms the bulk of iQur’s diagnostics wing, stemmed from research at the start of the company’s life. While diagnostics are no longer the focus of the company’s work, it is this that launched iQur (originally ‘HepCGen’) in 2003: iQur was born from the hope to provide sophisticated, cost-effective testing for patients with hepatitis C.
The Enhanced Liver Fibrosis Test (ELF™) is a simple, accurate blood test for measuring liver damage (known as ‘fibrosis’).
Fibrotic damage to the liver results from many chronic conditions, including alcoholic liver disease, primary biliary cirrhosis and hepatitis. It is also caused by lifestyle choices, such as regular excessive drinking, binge drinking or eating an unhealthy diet.
Liver fibrosis remains unseen and may be symptomless for many years. The ELF Test is able to detect fibrosis at all stages of development, even in patients without symptoms of damage.
Unique to iQur, the ELF Test offers a quick and straightforward method of providing valuable information. It can be used
- with minimal patient discomfort,
- to identify significant liver disease,
- to monitor disease progression and response to therapy.
ELF combines three direct serum markers that have been shown to correlate to the level of liver fibrosis assessed by liver biopsy: hyaluronic acid, TIMP-1 and PIIINP. The combined measurement of these markers indicates the degree of fibrotic damage. ELF has been developed following intensive research by the European Liver Fibrosis Group in collaboration with Siemens Medical Solutions Diagnostics and the University of Southampton.
Designed to complement liver biopsies, ELF is CE marked and is available as a fully approved IVD test or for research use.